中药治疗表皮生长因子受体酪氨酸激酶抑制剂相关皮疹的Meta分析

Meta-analysis of traditional Chinese medicine in the treatment of skin rash caused by epidermal growth factor receptor tyrosine kinase inhibitor

目的 评价中药治疗表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）相关皮疹的疗效和安全性。方法 检索国内期刊公开发表的关于中药治疗EGFR-TKI相关皮疹的临床随机对照试验文献，对纳入的文献应用Jadad评分法进行质量评价，采用RevMan 5.2软件进行Meta分析。结果 共有6 条文献符合纳入标准，共纳入248例患者，其中治疗组133例，对照组115例；患者年龄30～75岁。与对照组比较，中药治疗EGFR-TKI相关皮疹临床疗效的合并OR值为7.51，95 %可信区间为4.46～12.65。结论 Meta分析结果显示中药治疗EGFR-TKI相关皮疹的疗效较西药好，且不良反应鲜见，安全性好，可在临床推广应用。

Objective To evaluate the efficacy and safety of traditional Chinese medicine in the treatment of skin rash caused by epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI）. Methods The clinical randomized controlled trials of traditional Chinese medicine in the treatment of EGFR-TKI-induced skin rash which published in domestic journals were selected. The quality assessment of included literature was made by Jadad score, RevMan 5.2 software was used to make Meta-analysis. Results A total of 6 studies met the inclusion criteria, the 6 studies included 248 patients, 133 cases in the treatment group, 115 cases in the control group. All patients were 30 to 75 years old. Compared with the control group, the combined OR value of the clinical efficacy of traditional Chinese medicine in the treatment of EGFR-TKI-induced rash was 7.51, with 95 % confidence interval 4.46-12.65. Conclusions Meta-analysis shows that the clinical efficacy of traditional Chinese medicine in the treatment of EGFR-TKI-induced skin rash is better than Western medicine, and no adverse reactions. It can be widely used in clinical practice.